Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phosphocreatine injection in heart failure with sarcopenia
ChiCTR2000032916Phase 4Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- May 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of phosphocreatine in heart failure (HF) and Sarcopenia (2 arms), sponsored by Qilu Hospital of Shandong University. Primary endpoints: NT-proBNP, left ventricular ejection fraction and 4 more. Planned start May 2020; status: not yet recruiting.
02
Drugs
phosphocreatine
03
Conditions
heart failure (HF)Sarcopenia
Beyond the preview
Go deeper on ChiCTR2000032916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032916.